ALIMP.PA Implanet SA

Healthcare Health Care Equipment & Supplies Euronext Paris
0.1338 EUR
Close of Nov 7, 2026
0.1280 0.2860
Market cap
EUR 19.2M
P/E
-
P/B
59.81x
ROE
-
Dividend yield
-
Fundamental score
0.8/5

Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.

Is ALIMP.PA undervalued?

Graham number

The Graham number of Implanet SA cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Implanet SA fundamental analysis

2 of 11 checks passed

ROE 0/2

Negative ROE (-155.71%) indicates poor financial performance, raising concerns about profitability and efficiency in utilizing shareholders' equity.

ROA 0/2

The stock's ROA (-52.93%) indicates that it's not effectively utilizing its assets to generate profits, making it a less favorable option to invest and earn consistent returns.

PBV 2/2

With a remarkably low PBV ratio (0.28x), the stock offers substantial upside potential at a bargain price.

DER 0/2

The company has a high debt to equity ratio (192%), which means it owes a lot of money compared to what it actually owns, making it financially risky.

Revenue Growth 0/2

Company's revenue has remained stagnant over the past three years, indicating a lack of growth and making it a less favorable option.

Net Profit Growth 0/2

This company's net profit has remained flat over the past five years, suggesting a lack of growth and making it a less attractive investment opportunity.

Assets Growth 0/2

Company's revenue has stayed stagnant, showing no signs of improvement and making it a less favorable choice.

Graham Number 1/1

The Graham number of this company suggests that its stock price may be undervalued, indicating a potentially attractive investment opportunity.

Dividend Growth 0/2

The company's dividend growth has shown no improvement in the past three years, making it a less attractive investment option for those seeking increasing returns.

Dividend 0/2

The company has not distributed any dividends in the past three years, which may raise concerns for investors looking for regular income from their investments.

Buffet Intrinsic Value 0/1

The company's stock shows signs of being overvalued (0) according to Warren Buffett's formula, indicating a potential downside as its market price exceeds its estimated intrinsic value.

Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score

Implanet SA stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Implanet SA

Implanet S.A., together with its subsidiaries, manufactures and sells implants and medical instruments for orthopedic surgery in France, the United States, Europe, the Middle East, Africa, and internationally. The company offers spinal and knee products, including Jazz PF, Jazz Evo, Jazz Cap SP, Jazz Passer, Jazz Lock, Jazz Claw, Olea, Saxxo, Swingo, Shark, Origin, and Jazz Frame, as well as ISS-Jazz Screw systems for posterior fixation. It also provides an ultrasonic osteot…

Full company profile